Skip to main content

Table 2 Tumor characteristics of the eligible studies

From: Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis

Study

Staging system

Grading system

TN+/TN-

Stage 1–2/ 3–4

Grade 1–2/ 3–4

ccRCC/no-ccRCC

Tumor size (cm)

Xia et al.2017 [12]

2010 AJCC

Furman

41/252

212/81

248/45

293/0

NA

Wu et al.2017 [13]

2010 AJCC

Furman

77/224

265/36

225/76

301/0

NA

Niu et al.2017 [14]

2010 AJCC

Furman

75/309

295/89

255/129

384/0

Mean ± SD

4.1 ± 2.1

Kim et al.2017 [15]

2009 AJCC

Furman

46/131

60/82

44/105

159/3

Median (range)

8 (1–117)

Gu et al.2017 [16]

2010 AJCC

Furman

90/94

NA

70/94

161/23

NA

Gershman et al.2017 [17]

2010 AJCC

WHO/ ISUP

111/27

31/106

6/132

105/33

Median (range)

10(8–13)

Chen et al.2017 [18]

2010 AJCC

Furman

53/110

0/163

83/55

135/8

Mean ± SD

6.8 ± 3.5

Chang1 et al.2016 [19]

2010 AJCC

Furman

182/51

169/64

135/96

233/0

NA

Volpe et al.2016 [3]

2002 AJCC

Furman

60/130

190/0

155/35

156/34

Median (IQR)

4.9(3.5–7)

Khor et al.2016 [20]

2010 AJCC

Furman

665/177

630/212

265/577

842/0

Median (range)

4.2(0.6–20)

NguyenHoang et al.2016 [21]

2010 AJCC

Furman

78/294

292/100

259/133

392/0

Mean ± SD

4.3 ± 2.6

Errarte et al.2016 [22]

2010 AJCC

Furman

30/29

32/27

24/35

59/0

Median (range)

7.9(2–19)

Byun et al.2016 [23]

2002 AJCC

Furman

208/1076

1105/179

664/620

1114/170

Mean ± SD

4.08 ± 2.68

Huang et al.2015 [24]

2010 AJCC

Furman

34/184

160/58

155/63

0/218

Median (IQR)

3.5(2.5–6)

Cornejo et al.2015 [25]

NA

Fuhrman/ ISUP

40/114

121/33

103/51

0/154

Mean (range)

5.1(0.4–17)

Teng et al.2014 [26]

2009 AJCC

Furman

38/340

346/32

200/178

378/0

Mean ± SD

4.6 ± 2.6

Park et al.2014 [27]

NA

Furman

37/46

NA

13/70

83/0

NA

Oliveira et al.2014 [28]

2010 AJCC

Furman

18/76

77/17

65/29

94/0

Mean ± SD

4.7 ± 2.6

Can et al.2014 [29]

2010 AJCC

Furman

42/85

84/43

72/55

127/0

NA

Pichler et al.2013 [30]

2010 AJCC

Furman

277/717

723/271

839

804/190

NA

Kruck et al.2013 [31]

2010 AJCC

Furman

114/164

169/109

234/44

278/0

Mean ± SD

5.26 ± 2.91

Fukatsu et al.2013 [32]

2010 AJCC

Furman

57/104

508/53

341/220

561/0

NA

Sukov et al.2013 [33]

2010 AJCC

Furman

186/209

346/49

247/148

0/395

NA

Chang2 et al.2011 [34]

2002 AJCC

Furman

139/189

240/88

216/112

232/96

NA

Leibovich et al.2010 [35]

2002 AJCC

Furman

792/2090

1992/1070

1649/1413

1781/1281

NA

Katz et al.2010 [36]

2002 AJCC

Furman

253/586

575/194

589/252

641/198

NA

Roos et al.2009 [37]

2002 AJCC

Furman

10/108

0/118

63/55

109/16

Median (range)

8(2.5–20)

Coons et al.2009 [38]

2002 AJCC

Furman

57/71

0/128

40/103

105/23

Median (range)

9.9 (3.5–21)

Pflanz et al.2008 [39]

2002WHO

Thoenes

155/452

515/92

532/75

479/128

NA

Lee et al.2006 [40]

1997 AJCC

Furman

131/354

382/103

364/221

419/66

NA

Lam et al.2005 [41]

1997 AJCC

Fuhrman

168/143

157/153

186/119

270/41

NA

Tornberg et al.2016 [42]

2009 AJCC

Furman

84/58

0/132

38/104

129/13

Mean ± SD

10.3 ± 3.6

Schiavina et al.2015 [43]

2009 AJCC

Furman

49/136

0/185

46/139

150/35

Mean ± SD

8.05 ± 2.8

Ramsey et al.2008 [44]

1997 AJCC

Furman

55/28

48/35

37/40

33/50

NA

  1. total numbers rows:36; TN+/TN tumor necrosis positive/ tumor necrosis negative, SD standard deviation, NA data not applicable, ccRCC/no-ccRCC clear cell renal cell carcinoma/non- clear cell renal cell carcinoma